Synopsis: Anthem Biosciences will convert an additional Rs. 275 crore loan into Neoanthem equity, reducing loan exposure and increasing investment.
This Mid-cap Pharma Stock, engaged in contract research, development, and manufacturing of complex APIs, biologics like probiotics and enzymes, peptides, biosimilars, plus biotech services for global pharma clients, jumped 2.13 percent after the company converted Rs. 275 crores of loan into equity shares
With a market capitalization of Rs. 39,053.16 crores, the share of Anthem Biosciences Limited has reached an intraday high of Rs. 710.75 per equity share, rising nearly 2.13 percent from its previous day’s close price of Rs. 695.90. Since then, the stock has retreated and is currently trading at Rs. 694.55 per equity share.
Reason Behind the Surge:
Anthem Biosciences Limited has executed a First Amendment to its Loan Agreement with its wholly owned subsidiary, Neoanthem Lifesciences Private Limited, on February 23, 2026. The amendment enables the conversion of an additional Rs. 275 crore of loan into equity shares, within the overall sanctioned financial assistance limit of Rs. 550 crore. Earlier, Rs. 100 crore had already been converted into equity on February 21, 2025.
Following this conversion, the outstanding loan exposure will reduce by Rs. 275 crore, while the Company’s equity investment in Neoanthem will increase by the same amount, without any material impact on the consolidated financial statements.
Business Highlights:
Anthem Biosciences is supported by robust technology and infrastructure, with a strong workforce of 2,228 employees, including 1,097 scientific staff. The company has built significant scale with 400 KL of custom synthesis capacity and 142 KL of fermentation capacity. It has successfully commercialized 14 molecules, reflecting strong R&D capabilities and execution strength across CRDMO and specialty segments.
In Q3 FY26, Anthem Biosciences Limited’s revenue is primarily driven by its CRDMO segment, contributing 78.8 percent of total revenue, reflecting strong demand for integrated research and manufacturing services. The Specialty Ingredients segment accounts for 21.2 percent, providing additional diversification and supporting overall business stability and growth.
Anthem Biosciences Limited was founded in 2006 and is an Indian contract research, development and manufacturing organization (CRDMO) focused on pharmaceutical and biotechnology customers. It provides end-to-end services across discovery, development, and commercial manufacturing of small and large molecules from its facilities in and around Bengaluru, Karnataka.
Coming into financial highlights, Anthem Biosciences Limited’s revenue has decreased from Rs. 498 crore in Q3 FY25 to Rs. 423 crore in Q3 FY26, which is a drop of 15.06 percent. The net profit has also decreased by 25 percent from Rs. 124 crore in Q3 FY25 to Rs. 93 crore in Q3 FY26. Anthem Biosciences Limited’s revenue and net profit have grown at a CAGR of 23.86 percent and 37.13 percent, respectively, over the last five years.
In terms of return ratios, the company’s ROCE and ROE stand at 28.5 percent and 20.8 percent, respectively. Anthem Biosciences Limited has an earnings per share (EPS) of Rs. 8.64, and its debt-to-equity ratio is 0.04x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Anthem Biosciences Stock in Focus After Company Converts ₹275 Cr Loan into Equity Shares appeared first on Trade Brains.